OTLK OTLK
Company Profile ↓Company Overview
OTLK (OTLK) is a publicly traded company listed on with a market capitalization of $55.50M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR -15.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -15.06% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -48.76% |
| 6 Months: | +139.53% |
| 3 Months: | +325.62% |
| 1 Month: | -29.45% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)42.26 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -15.1% CAGR over 5 years.
- Trading 65.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.51M | -91.79K | -1.21M | 127.44K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 439.81K | 916.51K | 29.63K | 149.33K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.07M | -1.01M | -1.24M | -21.89K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.39M | 16.81M | 16.31M | 12.25M | 14.01M |
| Operating Income | -14.00M | -11.05M | -16.41M | -2.95M | -22.03M | -17.80M | -7.84M | -7.34M | -3.18M | -6.83M | -7.22M | -10.26M | -7.71M | -5.64M | -8.18M | -6.76M | -11.88M | -14.19M | -12.63M | -11.47M | -13.15M | -18.91M | -17.02M | -15.69M | -6.84M | -18.14M | -10.32M | -18.94M | -19.56M | - | -12.39M | -15.75M | -17.31M | -13.48M | -14.03M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.36M | -20.07M | -14.55M | -13.45M | -14.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.35K | 264.16K | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -46.35M | -20.15M | -14.85M | -23.06M | -4.45M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.80K | 0 | -1.55M | - | 0 |
| Net Income | -13.98M | -11.34M | -16.86M | -3.54M | -22.33M | -19.10M | -8.05M | -5.33M | -1.92M | -7.54M | -8.43M | -9.74M | -10.24M | -4.44M | -16.60M | -5.70M | -3.01M | -14.46M | -13.11M | -12.20M | -14.46M | -19.70M | -17.54M | -18.66M | -6.65M | -20.68M | -11.18M | -114.29M | 44.41M | - | -46.36M | -20.15M | -13.29M | -23.06M | -4.45M |
| Diluted EPS | - | - | - | -0.32 | -1.60 | - | -0.38 | -0.22 | - | -0.34 | -0.26 | - | - | - | - | - | -0.03 | -0.12 | -0.09 | -0.07 | -0.08 | -0.09 | -0.08 | -0.08 | -0.52 | -1.61 | -0.86 | -8.01 | -0.89 | 0.72 | -1.50 | -0.55 | - | -0.38 | -0.05 |
| R&D Expense | 10.15M | 9.68M | 12.73M | 4.14M | 12.02M | 13.23M | 4.12M | 4.16M | 402.40K | 5.16M | 5.80M | 6.07M | 5.94M | 4.34M | 5.85M | 4.38M | 8.49M | 11.95M | 8.53M | 8.55M | 9.87M | 12.22M | 11.25M | 9.86M | 544.95K | 11.10M | 4.53M | 13.51M | 11.20M | 9.66M | 4.41M | 7.13M | - | 3.63M | 4.50M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.22M | 2.98M | 3.81M | 3.09M | 8.15M | - | - | 0 | 0 | 0 | 1.41M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 0 | 1.36M |
| Gross Profit | - | - | - | - | - | - | - | - | - | 0 | 57.20K |
| Operating Expenses | - | - | - | - | - | - | - | 63.07M | 53.13M | 71.70M | 67.12M |
| Operating Income | -46.56M | -51.35M | -35.88M | -29.64M | -36.30M | -36.84M | - | -63.07M | -53.13M | -71.70M | -67.06M |
| EBITDA | - | - | - | - | - | - | - | -64.36M | -56.40M | -72.09M | -63.58M |
| Interest Expense | - | - | - | - | - | - | - | 1.49M | 2.53M | 3.16M | 283.13K |
| Pretax Income | - | - | - | - | - | - | - | -66.05M | -58.98M | -75.36M | -63.98M |
| Tax Provision | - | - | - | - | - | - | - | 2.80K | 2.80K | 2.80K | -1.55M |
| Net Income | -47.39M | -53.30M | -38.85M | -30.09M | -34.52M | -35.24M | - | -66.05M | -58.98M | -75.37M | -62.42M |
| Diluted EPS | - | -3.67 | -1.80 | -1.22 | - | -0.67 | - | -6.20 | -4.80 | -4.06 | -1.79 |
| R&D Expense | 38.88M | 32.76M | 23.81M | 18.50M | 23.81M | 26.34M | 38.96M | 42.33M | 26.45M | 41.76M | 27.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 35.01M | 25.41M | 20.73M | 22.28M | 17.13M | 19.73M | - | 28.53M | 32.30M | 28.82M | 18.58M |
| Current Assets | - | - | - | - | - | - | - | - | 27.52M | 30.98M | 27.42M | 17.39M |
| Cash & Equivalents | 2.35M | 9.07M | 2.35M | 3.19M | 1.72M | 8.02M | 12.54M | - | 17.40M | 23.39M | 14.93M | 8.08M |
| Inventory | - | - | - | - | - | - | - | - | - | - | 0 | 3.34M |
| Receivables | - | - | - | - | - | - | - | - | - | - | 0 | 1.49M |
| Total Liabilities | - | 62.56M | 30.58M | 51.46M | 43.09M | 27.90M | 16.91M | - | 19.79M | 46.74M | 101.90M | 50.77M |
| Current Liabilities | - | 37.04M | 20.44M | 28.74M | 32.04M | 20.29M | 15.89M | - | 19.73M | 46.73M | 42.55M | 45.81M |
| Long Term Debt | - | 2.92M | 2.23M | 151.11K | 98.49K | 50.28K | - | 10.89M | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | 10.96M | 35.56M | 29.74M | 30.19M |
| Total Equity | - | -54.22M | -5.17M | -33.65M | -25.54M | -16.13M | 2.83M | - | 8.74M | -14.44M | -73.08M | -32.19M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 11.37M | 13.01M | 23.91M | 53.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -15.51M | -33.04M | -32.29M | -31.79M | - | -56.67M | -42.97M | -68.79M | -51.83M |
| Investing Cash Flow | - | - | -292.09K | -2.78M | -437.31K | -900.00K | 0 | - | - | - | - |
| Financing Cash Flow | - | - | 16.63M | 34.35M | 39.03M | 37.21M | - | 59.59M | 48.97M | 60.33M | 44.98M |
| Capital Expenditure | -8.80M | -1.10M | -292.09K | -2.78M | -437.31K | - | - | - | - | - | - |
| Free Cash Flow | - | - | -15.80M | -35.82M | -32.73M | - | - | -56.67M | -42.97M | -68.79M | -51.83M |
| Net Change in Cash | - | - | - | - | - | - | - | 2.92M | 6.00M | -8.46M | -6.84M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | 4.0% |
| Operating Margin % | -892.1% | -1,723.3% | -941.4% | -960.1% | -445.6% | - | - | - | - | - | -4,744.3% |
| Net Margin % | -908.1% | -1,788.9% | -1,019.3% | -974.6% | -423.8% | - | - | - | - | - | -4,416.2% |
| ROE % | 87.4% | 1,030.4% | 115.4% | 117.8% | 214.0% | -1,246.8% | - | -756.0% | 408.5% | 103.1% | 193.9% |
| ROCE % | 2,290.4% | -1,033.3% | 448.3% | 303.8% | 1,150.5% | -958.5% | - | -716.9% | 368.1% | 522.2% | 246.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OTLK
Outlook Therapeutics Stock (OTLK) Opinions on FDA Approval of LYTENAVA - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSmZNMHZxMDN6OTJqTzZ3ZENKbTFiUTJMUEN0OGxteU1CTk1UYThVWVB4NEJpWTNiYmlnX090TjBYQUxmTDZIOENtUFo5ZnZHX0NVUVM3M1B0b3JMOXlUTFNVOXROOERZRlNxSkt5cnRuV0lBbjc3bFF4X0RWTzhlQXNCZndKYU9NdG1ubk…
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNRW1QeE15RHFPYnIxVVRtRUtjYlliXzlFZDl1NW5zaUVFdzhnaGlvaHBkdVRUdXQ0OWVId3g5ckRrV1JUanBwTS1nUWtPZnNjY29TWjdQcmN4TUtxTmtGTVhlaGNWeVZBLWZHWlZ6Q3ptQWFGNFJXcVBEcTY0TEhZcmF3Wk5wNk1FUWdmUV…
CVS Health Raised Its Outlook, but the Stock Still Fell - Barron's
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE15TmNVeUlESEFlVFJWV3BCaF9ubGNZVExhWldwWlBDUi16WUx3NWVxV1BGVm9yeDB4OTBHOXZUT1VkeG9GeHpiWnZXRGwwWHdwWFdjMC1TcTUzS3ItRHZZbGpUMmZ1aXBLR3BveVhMNmhBN195enNwVDhGTHNhdw?oc=5" target="_blan…
Amgen Boosts Sales View By $1 Billion After Smashing Views - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQSFVxUWRiaTRpakEwWklpdWdubmtRUjUtTVhCT0d2aUxYRHZ1Nml0ZEFUYUJKVlNjV0xWUDA5Xy1CMGduUHY4ZEVzeFNVLU5SaWVXS1FOOWZTODBhUWNRLV8wTndjNE55QnVRb2kxbEZxeXVuMXI4UkxkSG8yTUd0VWtRMA?oc=5" targe…
7 Wall Street analysts explain why you should buy the post-earnings dip in SpaceX stock - Business Insider
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxON2tpcWUwcXJrWkFPNDNsZjZ6cTh3aHhSM2ZBZWtCRDFKQXBrak5nNUhEbVlZeFM4Sno5azlEcHQ5N3Q2NnZsbHg2dlFOOXllQzdnem1Ual9nUV95OHpKcGNlZEtNa3NIUS1RREJLczFwZmJ3LVFRbkYyV25jUzdSMEp1V3M5WXJ4SElOQj…
FDA approves first eye-specific bevacizumab for wet AMD - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQR3hlYTdPY21QYnhqQ3NwOTRNS0dxYU9nejRQUUNvYk5WY19SMzVuLXhTTVMzME43V1JXekZHLVU5blZEMlA4bFlOVUdTbWZUeWV6aDJxeDg3NlpnamI0d1hjVmFpc1FSdk8yQlA5N2FfWjFmMndLX3VHMlV3Q2JESDZoWEFzYnRJNzNpRD…
OTLK — Frequently Asked Questions
What is the current share price of OTLK?
As of 2026-08-05 17:25 PDT, OTLK trades at $1.03 on NASDAQ/NYSE. Its 52-week range is $0.20 to $2.97.
What is the market capitalisation of OTLK?
OTLK has a market capitalisation of $55.50M on NASDAQ/NYSE.
What is the P/E ratio of OTLK?
OTLK trades at a trailing price-to-earnings (P/E) ratio of -0.58. Its price-to-book (P/B) ratio is -1.72.
Is OTLK a good stock to buy?
This page provides a data-driven analysis of OTLK, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.